Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,091–1,100 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1091
- Medicine slug
- nilotinib
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b46e09-62d2-4ce9-b3c0-deafcb1f1842 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6093952a-5248-45cb-ad17-33716a411146 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c67b81f-9a44-446a-a24f-bbecbbf88979 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Distribution Serum protein binding is approximately 98% with a blood-to-serum ratio of 0.68.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:805cc504-60bb-7743-5ada-679eb3badc7f (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e27c3e09-bc4f-4f01-be05-1c43ac72285d (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Distribution Serum protein binding is approximately 98% with a blood-to-serum ratio of 0.68.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b34e7fd4-53c5-46d8-bf8a-1fcbe7a16504 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8283672c-619f-fe60-3d25-040f95ac1440 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d288d165-3505-49bb-9b2e-124490d65f49 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Distribution Serum protein binding is approximately 98% with a blood-to-serum ratio of 0.68.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98b197ea-bca4-427e-8737-97f70a3262bc (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0bc799-ce6a-822a-e063-6394a90ab748 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Serum protein binding is approximately 98%.
Projected row 1092
- Medicine slug
- nilotinib
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 11
- Source count
- 10
- Agreement rate
- 0.7
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b46e09-62d2-4ce9-b3c0-deafcb1f1842 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6093952a-5248-45cb-ad17-33716a411146 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:805cc504-60bb-7743-5ada-679eb3badc7f (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b34e7fd4-53c5-46d8-bf8a-1fcbe7a16504 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8283672c-619f-fe60-3d25-040f95ac1440 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0bc799-ce6a-822a-e063-6394a90ab748 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Peak concentrations of nilotinib are reached 3 hours after oral administration.
3.3 hours
- Numeric value
- 3.3
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c67b81f-9a44-446a-a24f-bbecbbf88979 (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Absorption The median time (range) to reach peak plasma nilotinib concentrations (Tmax) is 3.3 hours (1.0 to 5.5) following single dose administration of Nilotinib Capsules 200 mg (0.5 times the maximum approved recommended dose) in fasted healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e27c3e09-bc4f-4f01-be05-1c43ac72285d (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
Absorption The median time (range) to reach peak plasma nilotinib concentrations (Tmax) is 3.3 hours (1.0 to 5.5) following single dose administration of Nilotinib Capsules 200 mg (0.5 times the maximum approved recommended dose) in fasted healthy subjects.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98b197ea-bca4-427e-8737-97f70a3262bc (opens source in a new tab)
Nilotinib label
Version not recorded · Effective date not recorded
The median time (range) to reach maximal plasma concentration (T max ) of nilotinib is 2 hours (1-8 hours) in the fasted state after oral administration.
Projected row 1093
- Medicine slug
- nimodipine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
13%
- Numeric value
- 13
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a323ebd8-ef1b-439b-93d1-ba73a5b0127d (opens source in a new tab)
Nimodipine label
Version not recorded · Effective date not recorded
Because of a high first-pass metabolism, the bioavailability of nimodipine averages 13% after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e660fa26-b5c4-4d6d-8887-9e22b6666a10 (opens source in a new tab)
Nimodipine label
Version not recorded · Effective date not recorded
Because of a high first-pass metabolism, the bioavailability of nimodipine averages 13% after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e65d5108-22a2-4d87-a78d-15606f3cc9e2 (opens source in a new tab)
Nimodipine label
Version not recorded · Effective date not recorded
Because of a high first-pass metabolism, the bioavailability of nimodipine averages 13% after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f829de8b-fabd-4aec-ac8d-c9aaef7be55b (opens source in a new tab)
Nimodipine label
Version not recorded · Effective date not recorded
Because of a high first-pass metabolism, the bioavailability of nimodipine averages 13% after oral administration.
Projected row 1094
- Medicine slug
- nintedanib
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
4.7%
- Numeric value
- 4.7
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da1c9f37-779e-4682-816f-93d0faa4cfc9 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e12f080-fcb4-465f-b988-4fa2c79f49aa (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b14164fb-0276-4ad1-a5ff-400ab9e292da (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:572722d7-338a-e4d2-e063-6394a90a257c (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecf7f05-4a95-b98c-e063-6394a90ab896 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f8600d-0974-51ca-6f8e-28c48a379e08 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b72b26c3-7731-80c0-734b-a5f53a1d89ae (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43dae004-eaf6-4411-8c3d-db7ab2c3b41e (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751c3473-35d6-47d6-b405-af16a989716c (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d017c42-a823-452d-bc6f-0491dd9823e3 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60d8104e-cb6c-4f4f-8159-95ed57346ffa (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
The absolute bioavailability of a 100 mg dose was 4.7% (90% CI: 3.62 to 6.08) in healthy volunteers.
Projected row 1095
- Medicine slug
- nintedanib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
9.5 hours
- Numeric value
- 9.5
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da1c9f37-779e-4682-816f-93d0faa4cfc9 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e12f080-fcb4-465f-b988-4fa2c79f49aa (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b14164fb-0276-4ad1-a5ff-400ab9e292da (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:572722d7-338a-e4d2-e063-6394a90a257c (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecf7f05-4a95-b98c-e063-6394a90ab896 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f8600d-0974-51ca-6f8e-28c48a379e08 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b72b26c3-7731-80c0-734b-a5f53a1d89ae (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43dae004-eaf6-4411-8c3d-db7ab2c3b41e (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751c3473-35d6-47d6-b405-af16a989716c (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d017c42-a823-452d-bc6f-0491dd9823e3 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60d8104e-cb6c-4f4f-8159-95ed57346ffa (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
Elimination The effective half-life of nintedanib in patients with IPF was 9.5 hours (gCV 31.9%).
Projected row 1096
- Medicine slug
- nintedanib
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 11
- Source count
- 11
- Agreement rate
- 0.818182
- Recorded readings
1050 L
- Numeric value
- 1,050
- Unit
- L
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da1c9f37-779e-4682-816f-93d0faa4cfc9 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e12f080-fcb4-465f-b988-4fa2c79f49aa (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (Vss: 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b14164fb-0276-4ad1-a5ff-400ab9e292da (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:572722d7-338a-e4d2-e063-6394a90a257c (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ecf7f05-4a95-b98c-e063-6394a90ab896 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43dae004-eaf6-4411-8c3d-db7ab2c3b41e (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:751c3473-35d6-47d6-b405-af16a989716c (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d017c42-a823-452d-bc6f-0491dd9823e3 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60d8104e-cb6c-4f4f-8159-95ed57346ffa (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1050 L) was observed.
1,050 L
- Numeric value
- 1,050
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f8600d-0974-51ca-6f8e-28c48a379e08 (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (Vss: 1,050 L) was observed.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b72b26c3-7731-80c0-734b-a5f53a1d89ae (opens source in a new tab)
Nintedanib label
Version not recorded · Effective date not recorded
After intravenous infusion, a high volume of distribution which was larger than total body volume (V ss : 1,050 L) was observed.
Projected row 1097
- Medicine slug
- nisoldipine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
5%
- Numeric value
- 5
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a5fb6a2-9fae-4872-8c5c-0f1ba03a57cb (opens source in a new tab)
Nisoldipine label
Version not recorded · Effective date not recorded
The absolute bioavailability of nisoldipine is about 5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:589157fa-d129-4de3-be3d-e0e1c22c5873 (opens source in a new tab)
Nisoldipine label
Version not recorded · Effective date not recorded
The absolute bioavailability of nisoldipine is about 5%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a52b773a-44f9-442f-a4be-39f79a558bd2 (opens source in a new tab)
Nisoldipine label
Version not recorded · Effective date not recorded
The absolute bioavailability of nisoldipine is about 5%.
Projected row 1098
- Medicine slug
- nitazoxanide
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
70%
- Numeric value
- 70
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0dc0656-3c46-43f9-adea-5285c522cef8 (opens source in a new tab)
Nitazoxanide label
Version not recorded · Effective date not recorded
The relative bioavailability of the suspension compared to the tablet was 70%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd3652fa-a183-4fb6-9a21-73fbeba6fc4b (opens source in a new tab)
Nitazoxanide label
Version not recorded · Effective date not recorded
The relative bioavailability of the suspension compared to the tablet was 70%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40a7cc30-76cd-49fe-965a-7823c4140d0f (opens source in a new tab)
Nitazoxanide label
Version not recorded · Effective date not recorded
The relative bioavailability of the suspension compared to the tablet was 70%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:295011e1-f919-4e5a-b9e7-4c784f623a86 (opens source in a new tab)
Nitazoxanide label
Version not recorded · Effective date not recorded
The relative bioavailability of the suspension compared to the tablet was 70%.
Projected row 1099
- Medicine slug
- nitisinone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 8
- Agreement rate
- 1
- Recorded readings
54 hours
- Numeric value
- 54
- Unit
- hours
- Source records
- 8
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 8 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7c38003-6899-4508-a69a-aef1231de22c (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:645c8387-30d5-4a86-a5d8-2f6b5df6d5f0 (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d449b73-d503-4132-b978-d890491975df (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc5e4875-fcd7-408c-88c9-4a715f4384b6 (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cec0318-9f55-4340-b14b-588635619251 (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:437868f5-1c9e-4b0f-8a03-77df8ac0900d (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1b3adc8-02fa-4e22-8c05-8f32b586e53f (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00307f42-748d-4227-8c6f-ed5f0a89ae0a (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Elimination The mean terminal plasma half-life of single dose nitisinone in healthy male subjects is 54 hours.
Projected row 1100
- Medicine slug
- nitisinone
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 10
- Source count
- 3
- Agreement rate
- 0.666667
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d449b73-d503-4132-b978-d890491975df (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Compared to ORFADIN capsule, the median T max occurred about 3 hours earlier with ORFADIN oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00307f42-748d-4227-8c6f-ed5f0a89ae0a (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Compared to ORFADIN capsule, the median T max occurred about 3 hours earlier with ORFADIN oral suspension.
3.5 hours
- Numeric value
- 3.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cf67e24-d46b-4376-bbd0-0b973c406d0d (opens source in a new tab)
Nitisinone label
Version not recorded · Effective date not recorded
Absorption Nitisinone time to C max (T max ) is 3.5 hours (median, ranging from 1 to 4 hours) following single oral administration of 10 mg (5 times the recommended dosage) nitisinone under fasting conditions.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1090Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.